Personal information

Other IDs

Scopus Author ID: 56580140700
Scopus Author ID: 35181646700

Countries

Finland

Activities

Collapse all

Employment (1)

Kuopio University Hospital: Kuopio, FI

2017-03-15 to present | MD, PhD, oncology trainee (Cancer centre)
Employment
Source: Self-asserted source
Aino Rönkä

Education and qualifications (2)

Itä-Suomen yliopisto - Kuopion kampus: Kuopio, FI

2009-01-01 to 2015-04-01 | PhD (Clinical microbiology)
Education
Source: Self-asserted source
Aino Rönkä

Itä-Suomen yliopisto - Kuopion kampus: Kuopio, FI

2006-08-01 to 2012-05-01 | MD (Medicine)
Education
Source: Self-asserted source
Aino Rönkä

Professional activities (2)

Suomen Onkologiayhdistys: Helsinki, FI

Membership
Source: Self-asserted source
Aino Rönkä

Suomen Lääkäriliitto: Helsinki, FI

Membership
Source: Self-asserted source
Aino Rönkä

Works (19)

Front‐line and second‐line treatment for mantle cell lymphoma in clinical practice: A multicenter retrospective analysis

European Journal of Haematology
2024-08 | Journal article
DOI: 10.1111/ejh.14219
Part of ISSN: 0902-4441
Part of ISSN: 1600-0609
Contributors: Minna Harmanen; marc sorigue; Madiha Khan; Roosa Prusila; Tuula Klaavuniemi; Esa Kari; Esa Jantunen; Kaisa Sunela; Aino Rajamäki; Erika Alanne et al.
Source: Self-asserted source
Aino Rönkä

Survival of patients with classical Hodgkin lymphoma in Finland: a national population-based analysis

Blood Cancer Journal
2024-08-20 | Journal article
DOI: 10.1038/s41408-024-01125-4
Part of ISSN: 2044-5385
Contributors: Noora Hannuksela; Anu Partanen; Anna Anttalainen; Liisa Ukkola-Vuoti; Iiro Toppila; Johanna Vikkula; Katja Marin; Hanne Kuitunen; Tatu Miettinen; Outi Kuittinen et al.
Source: Self-asserted source
Aino Rönkä

High Numbers of CD163+ Tumor-Associated Macrophages Predict Poor Prognosis in HER2+ Breast Cancer

Cancers
2024-02-01 | Journal article
DOI: 10.3390/cancers16030634
Contributors: Minna M. Jääskeläinen; Ritva Tumelius; Kirsi Hämäläinen; Kirsi Rilla; Sanna Oikari; Aino Rönkä; Tuomas Selander; Arto Mannermaa; Satu Tiainen; Päivi Auvinen
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors

BMC Cancer
2023-12-04 | Journal article
DOI: 10.1186/s12885-023-11699-0
Contributors: Satu Tiainen; Veera Nurmela; Tuomas Selander; Patrik Turunen; Sanna Pasonen-Seppänen; Tiia Kettunen; Outi Kuittinen; Päivi Auvinen; Aino Rönkä
Source: check_circle
Crossref

Previous radiotherapy improves treatment responses and causes a trend toward longer time to progression among patients with immune checkpoint inhibitor-related adverse events.

Cancer immunology, immunotherapy : CII
2023-07 | Journal article
DOI: 10.1007/s00262-023-03494-4
PMID: 37486396
Contributors: Jokimäki A; Hietala H; Lemma J; Karhapää H; Rintala A; Kaikkonen JP; Sunela K; Boman E; Jukkola A; Tiainen S et al.
Source: Self-asserted source
Aino Rönkä via Europe PubMed Central

Rapid diagnosis and initiation of treatment has a crucial role in the prognosis of primary central nervous system lymphoma.

British journal of haematology
2023-07 | Journal article
DOI: 10.1111/bjh.19003
PMID: 37519227
Contributors: Kuitunen H; Puhakka I; Rönkä A; Selander T; Jäkälä P; Arkko UM; Klaavuniemi T; Sunela K; Rajamäki A; Kuittinen O
Source: Self-asserted source
Aino Rönkä via Europe PubMed Central

The prognostic and predictive role of tumor-infiltrating lymphocytes (FoxP3 + and CD8 +) and tumor-associated macrophages in early HER2 + breast cancer.

Breast cancer research and treatment
2023-07 | Journal article
DOI: 10.1007/s10549-023-07017-8
PMID: 37428418
PMC: PMC10361875
Contributors: Jääskeläinen MM; Tiainen S; Siiskonen H; Ahtiainen M; Kuopio T; Rönkä A; Kettunen T; Hämäläinen K; Rilla K; Harvima I et al.
Source: Self-asserted source
Aino Rönkä via Europe PubMed Central

Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy

Clinical Lung Cancer
2023-06 | Journal article
DOI: 10.1016/j.cllc.2023.01.004
Contributors: Hannes Vihinen; Artturi Jokinen; Teemu D. Laajala; Nesna Wahid; Lotta Peltola; Tiia Kettunen; Aino Rönkä; Leena Tiainen; Tanja Skyttä; Laura Kohtamäki et al.
Source: check_circle
Crossref

Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study

Cancers
2023-02-20 | Journal article
DOI: 10.3390/cancers15041341
Contributors: Hanne K. Kuitunen; Aino L. K. Rönkä; Eila M. Sonkajärvi; Juha-Matti Isokangas; Marja Pyörälä; Kari A. A. Palosaari; Anna S. Jokimäki; Anu E. Partanen; Harri J. Littow; Merja A. Vakkala et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Survival of patients with mantle cell lymphoma in the rituximab era: Retrospective binational analysis between 2000 and 2020.

British journal of haematology
2022-12 | Journal article
DOI: 10.1111/bjh.18597
PMID: 36513500
Contributors: Harmanen M; Hujo M; Sund R; Sorigue M; Khan M; Prusila R; Klaavuniemi T; Kari E; Jantunen E; Sunela K et al.
Source: Self-asserted source
Aino Rönkä via Europe PubMed Central

Risk factors of venous thromboembolic events among diffuse large B-cell lymphoma patients receiving first-line treatment

2022-04 | Preprint
DOI: 10.21203/rs.3.rs-1478845/v2
PPR: PPR484333
Contributors: Jokimäki A; Tokola S; Harmanen M; Kuitunen H; Sillanpää A; Rönkä A; Selander T; Jukkola A; Auvinen P; Kuittinen O et al.
Source: Self-asserted source
Aino Rönkä via Europe PubMed Central

Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis.

BMC cancer
2022-03 | Journal article
DOI: 10.1186/s12885-022-09315-8
PMID: 35241020
PMC: PMC8895860
Contributors: Puhakka I; Kuitunen H; Jäkälä P; Sonkajärvi E; Turpeenniemi-Hujanen T; Rönkä A; Selander T; Korhonen M; Kuittinen O
Source: Self-asserted source
Aino Rönkä via Europe PubMed Central

The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma.

Frontiers in oncology
2021-01 | Journal article
DOI: 10.3389/fonc.2021.811434
PMID: 35127523
PMC: PMC8813769
Contributors: Takabe P; Siiskonen H; Rönkä A; Kainulainen K; Pasonen-Seppänen S
Source: Self-asserted source
Aino Rönkä via Europe PubMed Central

Human memory CD4+ T cell response to the major dog allergen Can f 5, prostatic kallikrein

Clinical and Experimental Allergy
2016 | Journal article
DOI: 10.1111/cea.12694
EID:

2-s2.0-84964403884
Contributors: Kailaanmäki, A.; Kinnunen, T.; Rönkä, A.; Rytkönen-Nissinen, M.; Lidholm, J.; Mattsson, L.; Randell, J.; Virtanen, T.
Source: Self-asserted source
Aino Rönkä via Scopus - Elsevier

Characterization of human memory CD4<sup>+</sup> T-cell responses to the dog allergen Can f 4

Journal of Allergy and Clinical Immunology
2015 | Journal article
DOI: 10.1016/j.jaci.2015.02.025
EID:

2-s2.0-84943451380
Contributors: Rönkä, A.L.; Kinnunen, T.T.; Goudet, A.; Rytkönen-Nissinen, M.A.; Sairanen, J.; Kailaanmäki, A.H.T.; Randell, J.T.; Maillère, B.; Virtanen, T.I.
Source: Self-asserted source
Aino Rönkä via Scopus - Elsevier

Human CD4<sup>+</sup> T cell responses to the dog major allergen Can f 1 and its human homologue tear lipocalin resemble each other

PLoS ONE
2014 | Journal article
DOI: 10.1371/journal.pone.0098461
EID:

2-s2.0-84902153128
Contributors: Liukko, A.L.K.; Kinnunen, T.T.; Rytkönen-Nissinen, M.A.; Kailaanmäki, A.H.T.; Randell, J.T.; Maillère, B.; Virtanen, T.I.
Source: Self-asserted source
Aino Rönkä via Scopus - Elsevier

Mammal-derived respiratory lipocalin allergens do not exhibit dendritic cell-activating capacity

Scandinavian Journal of Immunology
2013 | Journal article
DOI: 10.1111/sji.12023
EID:

2-s2.0-84875633122
Contributors: Parviainen, S.; Kinnunen, T.; Rytkönen-Nissinen, M.; Nieminen, A.; Liukko, A.; Virtanen, T.
Source: Self-asserted source
Aino Rönkä via Scopus - Elsevier

Comparison of the allergic and nonallergic CD4+ T-cell responses to the major dog allergen Can f 1

Journal of Allergy and Clinical Immunology
2010 | Journal article
DOI: 10.1016/j.jaci.2010.06.005
EID:

2-s2.0-77955921841
Contributors: Parviainen, S.; Taivainen, A.; Liukko, A.; Nieminen, A.; RytkOnen-Nissinen, M.; Kinnunen, T.; Virtanen, T.
Source: Self-asserted source
Aino Rönkä via Scopus - Elsevier

Suboptimal recognition of a T cell epitope of the major dog allergen Can f 1 by human T cells

Molecular Immunology
2009 | Journal article
DOI: 10.1016/j.molimm.2009.07.022
EID:

2-s2.0-70349467752
Contributors: Juntunen, R.; Liukko, A.; Taivainen, A.; Närvänen, A.; Durand, G.; Kauppinen, A.; Nieminen, A.; Rytkönen-Nissinen, M.; Saarelainen, S.; Maillère, B. et al.
Source: Self-asserted source
Aino Rönkä via Scopus - Elsevier
How many people are using ORCID?